Our group has previously implicated myofibroblast-like cell proliferation in PVS [2,30], and our current treatment is aimed at tyrosine-kinase receptor inhibition using targeted anti-proliferative pharmacotherapy [9]. This evidence concerns the gene NTRK1 and perivascular space measurement.